Billing Code 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances

Notice of Application

Clinical Supplies Management, Inc.

Pursuant to Title 21 Code of Federal Regulations
1301.34 (a), this is notice that on July 22, 2013, Clinical
Supplies Management, Inc., 342 42<sup>nd</sup> Street South, Fargo,
North Dakota 58103, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as an
importer of Sufentanil (9740), a basic class of controlled
substance listed in schedule II.

The company plans to import the listed controlled substance with the sole purpose of packaging, labeling, and distributing to customers which are qualified clinical sites, conducting FDA-approved clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with D listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act 21 USC § 952 (a)(2)(B) may, in the circumstances set forth in

21 USC § 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43, and in such form as prescribed by 21 CFR § 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 30 DAYS FROM DATE OF PUBLICATION].

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 USC §

958(a); 21 USC § 823(a); and 21 CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: August 29, 2013

[FR Doc. 2013-21735 Filed 09/05/2013 at 8:45 am; Publication Date: 09/06/2013]